Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male with ≥ 1 diagnosis claim for prostate cancer
Have documented secondary metastasis code on or after the initial prostate cancer diagnosis
Have initiated enzalutamide or abiraterone within 90 days prior to the metastasis date or on or after the metastasis date. The initiation date of enzalutamide or abiraterone will be defined as the index date.
Have evidence of surgical or medical castration before the index date
At least 18 years old at the index date
Continuous eligibility for ≥ 12 months prior to the index date
You may not be if
Received chemotherapy, novel hormonal therapy, radium-223, or immunotherapy prior to the index date
Had a prior history of other cancers
Clareo Health | Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
